Zacks: Brokerages Anticipate Stryker Co. (NYSE:SYK) to Post $2.30 EPS

Wall Street analysts forecast that Stryker Co. (NYSE:SYK – Get Rating) will post earnings of $2.30 per share for the current quarter, according to Zacks Investment Research. Ten analysts have provided estimates for Stryker’s earnings. The lowest EPS estimate is $2.21 and the highest is $2.37. Stryker posted earnings of $2.25 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 2.2%. The business is expected to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Stryker will report full-year earnings of $9.64 per share for the current year, with EPS estimates ranging from $9.60 to $9.70. For the next financial year, analysts expect that the business will report earnings of $10.78 per share, with EPS estimates ranging from $10.35 to $11.05. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that cover Stryker.

Stryker (NYSE:SYK – Get Rating) last announced its quarterly earnings results on Thursday, April 28th. The medical technology company reported $1.97 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.95 by $0.02. The firm had revenue of $4.30 billion for the quarter, compared to analyst estimates of $4.19 billion. Stryker had a net margin of 11.56% and a return on equity of 24.09%. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.93 EPS.

SYK has been the topic of several analyst reports. BTIG Research boosted their price target on shares of Stryker from $273.00 to $278.00 in a report on Monday, April 18th. TheStreet lowered shares of Stryker from a “b” rating to a “c+” rating in a report on Monday. Evercore ISI reaffirmed an “outperform” rating and issued a $284.00 target price on shares of Stryker in a report on Tuesday, March 15th. Citigroup lowered their target price on shares of Stryker from $300.00 to $290.00 in a report on Friday, January 28th. Finally, Sanford C. Bernstein raised shares of Stryker from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $288.00 to $295.00 in a report on Wednesday, March 16th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $291.44.

Shares of Stryker stock opened at $237.87 on Wednesday. The firm has a market capitalization of $89.84 billion, a PE ratio of 45.22, a price-to-earnings-growth ratio of 2.72 and a beta of 0.99. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.98 and a quick ratio of 1.18. The company’s fifty day moving average price is $260.46 and its two-hundred day moving average price is $260.32. Stryker has a 52-week low of $230.16 and a 52-week high of $281.16.

Institutional investors have recently added to or reduced their stakes in the business. Claremont Financial Group Inc. acquired a new position in Stryker during the 1st quarter valued at about $25,000. Retirement Group LLC lifted its position in Stryker by 86.8% during the 4th quarter. Retirement Group LLC now owns 99 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 46 shares during the period. Cassady Schiller Wealth Management LLC bought a new stake in shares of Stryker in the 4th quarter valued at about $27,000. Exane Derivatives bought a new stake in shares of Stryker in the 1st quarter valued at about $27,000. Finally, Disciplined Investments LLC bought a new stake in shares of Stryker in the 4th quarter valued at about $28,000. Institutional investors own 74.52% of the company’s stock.

Stryker Company Profile (Get Rating)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.

See Also